![Immunofluorescence using cos-7 cells transfected or mock transfected with a plasmid containing the full length LYPD3 reading frame. One set of cells were fixed with 4% paraformaldehyde and stained with anti-LYPD3 [11F1] followed by anti-mouse FITC (upper panel). Another set of cells were fixed with 4% paraformaldehyde; permeabilised with 0.1% Triton X-100a nd stained with anti-LYPD3 [11F1] followed by the same FITC conjugated anti-mouse monoclonal.](https://cancertools.org/wp-content/uploads/19a8bb81-b81f-4e2a-a69b-c12a55310088.png)
Cat. #152660
Anti-LYPD3 [11F1]
Cat. #: 152660
Sub-type: Primary antibody
Unit size: 100 ug
Target: Ly6/PLAUR domain-containing protein 3
Class: Monoclonal
Application: FACS ; IF
Reactivity: Human
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Institute: A*STAR Accelerate Technologies Pte Ltd
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-LYPD3 [11F1]
- Research fields: Cell biology
- Clone: 11F1
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Reactivity: Human
- Host: Mouse
- Application: FACS ; IF
- Description: LYPD3 (Ly6/PLAUR domain-containing protein 3) also known as C4.4A, is a structural homologue of the urokinase receptor, uPAR, which constitutes a well-established prognostic marker in various human cancers. It consists of 346 amino acids and is glycosylphosphatidylinositol (GPI)-anchored, and its extracellular domains are composed of two modules belonging to the Ly6/uPAR/ÄÂ?-neurotoxin (LU) protein domain family. LYPD3 is endogenously expressed in suprabasal cells of squamous epithelia and amnion membrane in human placenta. Currently, LYPD3 has no defined functions but inhibition of tumor cell migration with anti-LYPD3 antibody suggests its role in cell/cell, cell/matrix interaction and tumour invasion and metastasis.
- Immunogen: GST-LYPD3 (residues 31 to 326) fusion protein
- Isotype: IgG1
- Myeloma used: Sp2/0-Ag14
Target Details
- Target: Ly6/PLAUR domain-containing protein 3
- Target background: LYPD3 (Ly6/PLAUR domain-containing protein 3) also known as C4.4A, is a structural homologue of the urokinase receptor, uPAR, which constitutes a well-established prognostic marker in various human cancers. It consists of 346 amino acids and is glycosylphosphatidylinositol (GPI)-anchored, and its extracellular domains are composed of two modules belonging to the Ly6/uPAR/a-neurotoxin (LU) protein domain family. LYPD3 is endogenously expressed in suprabasal cells of squamous epithelia and amnion membrane in human placenta. Currently, LYPD3 has no defined functions but inhibition of tumor cell migration with anti-LYPD3 antibody suggests its role in cell/cell, cell/matrix interaction and tumour invasion and metastasis.
Applications
- Application: FACS ; IF
Handling
- Format: Liquid
- Concentration: 0.9-1.1 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -15° C to -25° C
- Shipping conditions: Shipping at 4° C
